/
CDIO
$2.08+$0.07 (+3.48%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.9M
3M shares
52-week range
$0.97 – $7.91
16% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Borrow rate
69.01%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-112.52
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $901 | $950 | $17.1K | $34.9K | $14.8K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $901 | $950 | $17.1K | $34.9K | $14.8K |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $1.5K | $31.5K | $40.4K | $145.2K | $228.0K | $641.2K |
| Operating income | −$609.2K | −$620.4K | −$4.5M | −$7.2M | −$8.4M | −$6.5M |
| EBITDA | −$598.5K | −$604.4K | −$4.6M | −$1.5M | −$8.1M | −$6.1M |
| Net income | −$605.2K | −$620.4K | −$4.7M | −$8.4M | −$8.4M | −$6.5M |
| Net margin | — | -68862.2% | -490630.0% | -49087.8% | -24028.2% | -43832.5% |
| EPS (diluted) | -0.06 | -1.96 | -45.30 | -19.80 | -9.30 | -3.71 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $25M | $-16.50 | $-16.50–$-16.50 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.23
Price
$2.08
Implied upside
+7%
Peer comparison
Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
www.cdio.ai- Employees
- 17
- IPO / List date
- Oct 26, 2022
- HQ
- CHICAGO, IL
Held by traders on TradeandTell
No one on the platform currently holds CDIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 15,348 | $29.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-05-13 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded CDIO yet.
